SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Lupus/Nephritis

 Public ReplyPrvt ReplyMark as Last ReadFileNext 10PreviousNext  
To: keokalani'nui who started this subject3/1/2001 4:06:41 PM
From: keokalani'nui  Read Replies (1) of 95
 
BMS, CTLA4Ig.

3/1/01 JOI:

CUTTING EDGE

Cutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide1
David I. Daikh2 and David Wofsy
Department of Medicine, Department of Veterans Affairs Medical Center and the University of California, San Francisco, CA 94121

Cyclophosphamide (CTX) prevents progression of nephritis and prolongs survival in (NZB x NZW)F1 (B/W) mice and is used to treat humans with lupus nephritis. To compare the efficacy of CTLA4Ig with CTX and determine whether there is an incremental benefit to combining CTLA4Ig with CTX, we treated B/W mice with CTX, CTLA4Ig, or both agents. In mice with mild renal disease, treatment delayed the onset of proteinuria and prolonged survival in all groups. In mice with advanced renal disease, treatment with both agents reduced proteinuria in 71% of mice, whereas mice treated with either agent alone had no such improvement. Survival was also markedly improved among mice treated with both agents. Thus, combination treatment with CTX and CTLA4Ig is more effective than either agent alone in reducing renal disease and prolonging survival of B/W mice with advanced nephritis. This striking reversal of proteinuria is unprecedented in animal models of SLE.

BMS has CTLA4Ig in PII. GZTC is preclincal with the goat version.

--Wilder
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFileNext 10PreviousNext